Skip to main content

METHOTREXATE INJECTION Shortage

Last Updated: May 26, 2016
Status: Resolved

Products Affected - Description
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 67457-0466-10
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 2 mL preservative-free vial, 5 count, NDC 67457-0467-99
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 4 mL preservative-free vial, 10 count, NDC 67457-0486-99
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 67457-0480-40
    • Methotrexate injection, Mylan Institutional, 25 mg/mL, 8 mL preservative-free vial, 10 count, NDC 67457-0485-99
Reason for the Shortage
    • Mylan Institutional cannot provide a reason for the shortage.
    • Sandoz discontinued methotrexate 2 mL and 10 mL vials.
    • Teva has methotrexate on short-term back order for standard quality control.
    • West-Ward Pharmaceuticals discontinued methotrexate injection in September 2014.
Available Products
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 10 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0010-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 15 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0015-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 20 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0020-04
    • Otrexup subcutaneous injection, Antares Pharm, Inc., 25 mg/0.4 mL, auto-injector, 4 count, NDC 54436-0025-04
    • Methotrexate injection, Accord, 25 mg/mL, 10 mL vial, 1 count, NDC 16729-0277-03
    • Methotrexate injection, Accord, 25 mg/mL, 2 mL preservative-free vial, 1 count, NDC 16729-0277-30
    • Methotrexate injection, Accord, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 16729-0277-35
    • Methotrexate injection, Fresenius Kabi, 25 mg/mL, 10 mL (with preservative) vial, 1 count, NDC 63323-0123-10
    • Methotrexate lyophilized powder for solution for injection, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0122-50
    • Methotrexate injection, Pfizer, 25 mg/mL, 2 mL (with preservative) vial, 5 count, NDC 61703-0350-38
    • Methotrexate injection, Pfizer, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 61703-0408-41
    • Methotrexate injection, Sandoz, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 66758-0041-01
    • Methotrexate injection, Teva, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 00703-3675-01
    • Methotrexate injection, Teva, 25 mg/mL, 2 mL preservative-free vial, 10 count, NDC 00703-3671-03
    • Methotrexate injection, Teva, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 00703-3678-01

Estimated Resupply Dates

    • Mylan Institutional has all methotrexate presentations on back order and the company cannot estimate a release date.
    • All other suppliers have product available.

Updated

Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 8, 2012 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer